The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.

Rehana Z HussainPeter V SguignaAnnette OkaiCrystal WrightMariam MadinawalaAnn D BassGary R CutterNavid ManouchehriOlaf Stüve

Published in: Journal of central nervous system disease (2022)

The SUPPRESS trial will provide clinical, imaging, and biological data to determine whether sequential natalizumab to alemtuzumab combination therapy establish a disease-free state in patients with relapsing forms of MS.

Keyphrases

multiple sclerosis
combination therapy
phase iii
clinical trial
study protocol
white matter
phase ii
high resolution
randomized controlled trial
open label
big data
stem cells
rheumatoid arthritis
machine learning
ms ms
mesenchymal stem cells
chemotherapy induced